VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
IMCRImmunocore Holdings plc
$28.60$1.5B
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksIMCREarnings History

IMCR logoImmunocore Holdings plc (IMCR) Earnings History

Net Loss

13 years of earnings data (2013–2025) · Currently unprofitable on a TTM basis

TTM Net Income
-$19M
● Net Loss
TTM EPS (Diluted)
$-0.36
Per share, diluted
YoY EPS Growth
+48.0%
Excellent
Net Margin
-8.9%
After-tax profitability
EPS Growth Rate (CAGR)
1YN/A
3YN/A
5YN/A
10YN/A
Operating Margin-11.3%
Gross Margin97.9%
Return on Equity-7.1%
Return on Assets-2.5%
Record Annual Net Income$20MFY2015
Record Quarterly EPS$0.25Q1 2026
Consecutive Profitable Years0years
Q1 2026
Net Income$13M
EPS (Diluted)$0.25
YoY Growth+48.0%Excellent
QoQ Growth+158.2%Excellent

Loading earnings history...

Immunocore Holdings plc (IMCR) Earnings Overview

As of June 22, 2026, Immunocore Holdings plc (IMCR) reported trailing twelve-month net income of -$19M, reflecting +48.0% year-over-year growth. The company earned $-0.36 per diluted share over the past four quarters, with a net profit margin of -8.9%.

Looking at the long-term picture, IMCR's historical earnings data spans multiple years. The company achieved its highest annual net income of $20M in fiscal 2015.

Immunocore Holdings plc is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →

Compared to peers including KYMR (-$315M net income, -794.4% margin), RCUS (-$369M net income, -142.9% margin), AGEN ($65M net income, 0.1% margin), IMCR has outperformed on profitability metrics. Compare IMCR vs KYMR →

IMCR Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
IMCR logoIMCRCurrent
-$19M$-0.36-8.9%-7.1%+48.0%—
KYMR logoKYMR
-$315M$-3.23-794.4%-25.8%-23.8%
RCUS logoRCUS
-$369M$-2.94-142.9%-63.3%-4.8%
AGEN logoAGEN
$65M$1.690.1%-+100.0%
MGNX logoMGNX
-$70M$-1.11-49.9%-86.9%-10.3%
FATE logoFATE
-$130M$-1.08-2051.1%-51.8%+29.9%
Best in group
Lowest in group

IMCR Historical Earnings Data (2013–2025)

13 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025-$26M+35.3%-$34M$-0.53-8.9%-11.3%
2024-$41M+6.7%-$56M$-1.02-16.5%-22.7%
2023-$44M-0.7%-$47M$-0.89-22.2%-23.9%
2022-$43M+67.4%-$43M$-0.95-30.1%-29.7%
2021-$133M-80.1%-$129M$-3.00-493.4%-478.5%
2020-$74M+28.7%-$86M$-2.33-246.0%-286.2%
2019-$104M-45.1%-$118M$-3.81-404.9%-460.9%
2018-$72M-8.9%-$93M$-2.62-302.8%-395.1%
2017-$66M-131.5%-$91M$-26.74-343.1%-473.7%
2016-$28M-242.9%-$40M$-11.60-140.5%-197.3%
2015$20M+320.3%-$20M$0.00117.4%-119.2%
2014-$9M-51.3%-$12M$-4.08-87.7%-114.6%
2013-$6M--$8M$0.00-180.6%-234.3%

Download Data

Export IMCR earnings history in CSV or JSON format

Free sign-in required to download data

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

13+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

IMCR — Frequently Asked Questions

Quick answers to the most common questions about buying IMCR stock.

What is IMCR earnings per share (EPS)?

IMCR trailing twelve-month (TTM) diluted EPS is $-0.36, reflecting +48.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2013 to 2025 is available in the table on this page.

What is Immunocore Holdings plc's net income?

Immunocore Holdings plc (IMCR) trailing twelve-month net income is $-19M as of 2025. Earnings grew +48.0% year-over-year.

Is IMCR profitable?

IMCR is not currently profitable on a TTM basis, reporting a net loss of $-19M. Net margin is -8.9%. Investors should monitor for a return to profitability.

What is IMCR's earnings growth rate?

IMCR compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2013 to 2025.

What are IMCR's profit margins?

Immunocore Holdings plc net profit margin is -8.9%, operating margin is -11.3%, and gross margin is +97.9%. Below-average margins reflect competitive or cost pressures. Return on Equity is -7.1%.

Is IMCR growing earnings?

Yes, IMCR earnings are accelerating — EPS growth of +48.0% exceeds the 5-year CAGR of N/A. TTM net income reached $-19M. Earnings momentum is strengthening.

What was IMCR's best earnings year?

Immunocore Holdings plc's highest annual net income on record is $20M, achieved in fiscal year 2015. Earnings history on this page spans 2013 to 2025 and includes all annual and quarterly figures.

What were IMCR's earnings last quarter?

IMCR's most recent reported quarter was Q1 2026. Net income was $13M with diluted EPS of $0.25. For a full breakdown of all quarters, see the quarterly earnings table on this page.

IMCR Earnings Over Time (2013–2025)

Net income & EPS — annual and quarterly view